ASN007
Based on 10 publication(s) in Google Scholar
ASN007 (ERK-IN-3) is a potent and orally active inhibitor of ERK. ASN007 inhibits ERK1/2 with low single-digit nM IC50 values. ASN007 exhibits significant anti proliferative activity against various tumor cells. ASN007 can be used for the research of cancers driven by RAS mutations.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.48%
- CAS No.: 2055597-12-9
- Formule: C22H25ClFN7O2
- Masse moléculaire:473.93
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-15816
UlixertinibERK1/2 Inhibitor -
HY-101494
TemuterkibERK1/ERK2 Inhibitor -
HY-15947
RavoxertinibERK1/2 Inhibitor -
HY-50846
SCH772984ERK1/2 Inhibitor -
HY-10999
TrametinibMEK Inhibitor -
HY-15816A
Ulixertinib hydrochlorideERK1/2 Inhibitor -
HY-126288
ASTX029ERK1/2 Inhibitor -
HY-128341
ERK5-IN-2ERK5 Inhibitor -
HY-112181
KO-947ERK1/2 Inhibitor -
HY-111483
Tizaterkib -
HY-13319
JNK-IN-8JNK Inhibitor -
HY-18932
DEL-22379ERK Dimerization Inhibitor
Publications Citing Use of MedChemExpress (MCE) ASN007
More- Nat Commun. 2025 Dec 17;16(1):11181. [Abstract]
- Phytomedicine. 2024 Dec:135:156022. [Abstract]
- NPJ Precis Oncol. 2026 Apr 8;10(1):211. [Abstract]
- Proc Natl Acad Sci U S A. 2026 Aug 18;123(33):e2532767123.
- Antioxidants (Basel). 2024 Oct 25;13(11):1296. [Abstract]
- Free Radic Biol Med. 2026 Jul 1:S0891-5849(26)00918-4.
- Biomed Mater. 2026 Jul 13;21(4). [Abstract]
- BJA Open. 2025 Feb 3:13:100376. [Abstract]
- Universite Laval. 2026.
- Preprints. 2024 Sep 11.
Customer Validation & Images
-
In Vivo Efficacy Study
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
Activité biologique
Description
IC50 & Target
[1]|
ERK1 |
ERK2 |
In Vitro
ASN007 (ERK-IN-3) inhibits the phosphorylation of ERK1/2 substrates such as RSK1, FRA1, and Elk1 in various cell lines[1].
ASN007 showes single-digit nanomolar antiproliferative activity that is selective for MAPK-pathway dependent cancer cell lines[1].
ASN007 (0.0005-10 µM, 60 min) can selectively inhibit ERK1/ERK2 enzymes (IC50 = 2 nM)[2].
ASN007 (4 h) dose dependently inhibits RSK1 (Ser380) phosphorylation in HT-29 cells[2].
ASN007 (15 min-72 h) rapidly (15 minutes) and persistently (72 hours) inhibits p-MSK1 and p-RSK1 in HT-29 cells[2].
ASN007 (0.0005-10 µM, 72 h) is sensitive to RAS/RAF mutant cell lines (median IC50 = 37 nM)[2].
ASN007 (24-72 h) can induce G0/G1 phase cell cycle arrest in various cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2055597-12-9
-
Appearance Solid
-
Masse moléculaire 473.93
-
Formule C22H25ClFN7O2
-
Color White to light yellow
-
SMILES
O=C(C1=CN(C2=NC(NC3CCOCC3)=NC=C2C)C=N1)N[C@@H](C4=CC(F)=CC(Cl)=C4)CN
-
Synonyms
ERK-IN-3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Supporting cells orchestrate noise-induced hearing loss via a Gasdermin D-dependent signaling loop with hair cells. [Abstract]2025 Dec 17;16(1):11181. PMID: 41407982 -
Phytomedicine
Hypocrellin A against intrahepatic Cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways. [Abstract]2024 Dec:135:156022. PMID: 39284270
ASN007 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Dec:135:156022. [Abstract]
ASN007 (0-60 μM; 24 h) showed antiproliferative activity and had an IC50 of 17.23 μM for RBE and 25.67 μM for HuccT1 cells.
-
NPJ Precis Oncol
High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer. [Abstract]2026 Apr 8;10(1):211. PMID: 41951768 -
-
Antioxidants (Basel)
Ellagic Acid Reduces Cadmium Exposure-Induced Apoptosis in HT22 Cells via Inhibiting Oxidative Stress and Mitochondrial Dysfunction and Activating Nrf2/HO-1 Pathway. [Abstract]2024 Oct 25;13(11):1296. PMID: 39594438
ASN007 purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 Oct 25;13(11):1296. [Abstract]
ASN007 (0, 5, 10 μM; a duration of 2 h; co-treated with CdSO4 at a concentration of 10 μM for an additional 24 h) did not affect CdSO4-induced cytotoxicity in HT22 cells.
-
-
Biomed Mater
Dual-engineered small extracellular vesicles targeted delivery miR-126 for reducing age-related bone loss. [Abstract]2026 Jul 13;21(4). PMID: 42309139 -
BJA Open
The concerted actions of microRNA-29a and interferon-β modulate complete Freund's adjuvant-induced inflammatory pain by regulating the expression of type 1 interferon receptor, interferon-stimulated gene 15, and p-extracellular signal-regulated kinase. [Abstract]2025 Feb 3:13:100376. PMID: 39980495
ASN007 purchased from MedChemExpress. Usage Cited in: BJA Open. 2025 Feb 3:13:100376. [Abstract]
ASN007 (30 μg; intrathecal (i.t.) injection) reversed the mechanical hyperalgesia induced by the miR-29a mimic for 1 h in rats.
ASN007 purchased from MedChemExpress. Usage Cited in: BJA Open. 2025 Feb 3:13:100376. [Abstract]
ASN007 (30 μg; intrathecal (i.t.) injection) showed no effect on the p-ERK and IFNR1 expression. While miR-29a mimic significantly increased the expression of p-ERK and decreased the expression of type 1 interferon receptor (IFNR1) in rats.
-
-
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (211.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% Methyl cellulose/0.5% Tween-80 in Saline water
Solubility: 6.67 mg/mL (14.07 mM); Suspended solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1100 mL | 10.5501 mL | 21.1002 mL | 52.7504 mL |
| 5 mM | 0.4220 mL | 2.1100 mL | 4.2200 mL | 10.5501 mL | |
| 10 mM | 0.2110 mL | 1.0550 mL | 2.1100 mL | 5.2750 mL | |
| 15 mM | 0.1407 mL | 0.7033 mL | 1.4067 mL | 3.5167 mL | |
| 20 mM | 0.1055 mL | 0.5275 mL | 1.0550 mL | 2.6375 mL | |
| 25 mM | 0.0844 mL | 0.4220 mL | 0.8440 mL | 2.1100 mL | |
| 30 mM | 0.0703 mL | 0.3517 mL | 0.7033 mL | 1.7583 mL | |
| 40 mM | 0.0528 mL | 0.2638 mL | 0.5275 mL | 1.3188 mL | |
| 50 mM | 0.0422 mL | 0.2110 mL | 0.4220 mL | 1.0550 mL | |
| 60 mM | 0.0352 mL | 0.1758 mL | 0.3517 mL | 0.8792 mL | |
| 80 mM | 0.0264 mL | 0.1319 mL | 0.2638 mL | 0.6594 mL | |
| 100 mM | 0.0211 mL | 0.1055 mL | 0.2110 mL | 0.5275 mL |
ASN007 Related Classifications
HY-136579 Related Classifications
Powered by Bioz